Recent Updates
Recently added Catalysts
ACRS Positive Sentiment Score: 70/100

Aclaris Therapeutics to Participate in the H.C. Wainwright 4th Annual Inflammatory Skin Disease Virtual Conference

Key Takeaway: Aclaris Therapeutics, Inc. will participate in the H.C. Wainwright 4th Annual Inflammatory Skin Disease Virtual Conference on April 14, 2026, at 12:00 PM EDT. The event will feature CEO Dr. Neal Walker and senior leadership discussing the company's initiatives and research. A live webcast of the conference will be available on Aclaris' website, along with an archived version accessible for at least 30 days. This participation highlights Aclaris' commitment to addressing treatment gaps in immuno-inflammatory diseases.

Market Sentiment Analysis

POSITIVE FACTORS

  • Aclaris Therapeutics is participating in a prominent industry conference.
  • The company is focused on immuno-inflammatory diseases with an innovative pipeline.
  • Aclaris aims to address unmet medical needs in their target patient population.

Full Press Release Details

WAYNE, Pa., April 08, 2026 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced that on Tuesday, April 14, 2026, at 12:00 PM EDT, Aclaris’ Chief Executive Officer Dr. Neal Walker and other members of Aclaris’ senior leadership team will participate in a fireside chat during the H.C. Wainwright 4th Annual Inflammatory Skin Disease Virtual Conference.
A live and archived webcast of this event will be accessible on the Events page of the Aclaris website, www.aclaristx.com. The webcast will be available on the Aclaris website for at least 30 days.
About Aclaris Therapeutics, Inc.
Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing a pipeline of novel product candidates to address the needs of patients with immuno-inflammatory diseases who lack satisfactory treatment options. The company has a multi-stage portfolio of product candidates powered by a robust R&D engine. For additional information, please visit www.aclaristx.com and follow Aclaris on LinkedIn.
Aclaris Therapeutics Contact:
Senior Vice President
Corporate Communications and Investor Relations

Frequently Asked Questions

When is Aclaris' fireside chat scheduled?

The fireside chat is on April 14, 2026, at 12:00 PM EDT.

Where can I watch the Aclaris fireside chat?

The chat can be viewed live and archived on Aclaris' website.

What does Aclaris Therapeutics focus on?

Aclaris focuses on developing treatments for immuno-inflammatory diseases.

How long will the webcast be available?

The webcast will be available for at least 30 days on Aclaris' site.

Who is Aclaris' CEO?

Dr. Neal Walker is the CEO of Aclaris Therapeutics, Inc.

Last updated: Apr 8, 2026